SFX by Ex Libris Inc.

Title:	Substrate-targeting γ-secretase modulators
Source:	Nature [0028-0836] Kukar, Thomas yr:2008

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	He, G. "Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease." Nature 467.7311 (2010): 95-98.
description	2.	St, Gerold P. "Alzheimer's disease: Selectively tuning gamma-secretase." Nature 467.7311 (2010): 36-37.
description	3.	Rozzini, L. "Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors." International journal of geriatric psychiatry 22.4 (2007): 356-60.
description	4.	Mangialasche, F. "Alzheimer's disease: clinical trials and drug development." Lancet Neurology, The 9.7 (2010): 702-716.
description	5.	Li, Y M M. "Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1." Nature 405.6787 (2000): 689-94.
description	6.	Blennow, K. "Alzheimer's disease." The lancet 368.9533 (2006): 387-403.
description	7.	Pramanik, D. "Active Site Environment of Heme-Bound Amyloid β Peptide Associated with Alzheimer's Disease." Journal of the American Chemical Society 133.1 (2011): 81-87.
description	8.	Cipriani, G. "Outcomes of a computer-based cognitive rehabilitation program on Alzheimer's disease patients compared with those on patients affected by mild cognitive impairment." Archives of gerontology and geriatrics 43.3 (2006): 327-35.
description	9.	Talassi, E. "Effectiveness of a cognitive rehabilitation program in mild dementia (MD) and mild cognitive impairment (MCI): A case control study." Archives of gerontology and geriatrics 44.Suppl 1 (2007): 391-9.
description	10.	Obeso, Jose A. "Missing pieces in the Parkinson's disease puzzle." Nature Medicine 16.6 (2010): 653-661.
description	11.	Cummings, Jeffrey L. "Current therapeutic targets for the treatment of Alzheimer's disease." Expert Review of Neurotherapeutics 10.5 (2010): 711-728.
description	12.	Sabbagh, Marwan N. "Drug development for Alzheimer's disease: Where are we now and where are we headed?" The American journal of geriatric pharmacotherapy 7.3 (2009): 167-185.
description	13.	St, John C H. "Will anti-amyloid therapies work for Alzheimer's disease?" Lancet, The 372.9634 (2008): 180-2.
description	14.	Hartmann, T. "Alzheimer's disease: the lipid connection." Journal of neurochemistry 103Suppl1.s1 (2007): 159-70.
description	15.	Filpula, D. "Antibody engineering and modification technologies." Biomolecular engineering 24.2 (2007): 201-215.
description	16.	Tennstedt, Sharon D. "Effect of memory impairment on training outcomes in ACTIVE." Journal of the International Neuropsychological Society 13.6 (2007): 953-960.
description	17.	Mucke, L. "Alzheimer's disease." Nature 461.7266 (2009): 895-897.
description	18.	Cummings, Jeffrey L L. "Alzheimer's disease." The New England journal of medicine 351.1 (2004): 56-67.
description	19.	Gauthier, S. "Improvement of Episodic Memory in Persons with Mild Cognitive Impairment and Healthy Older Adults: Evidence from a Cognitive Intervention Program." Dementia and geriatric cognitive disorders 22.5 (2006): 486-99.
description	20.	Wolfe, M. "Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease." Biochemistry 38.15 (1999): 4720-4727.